3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)

NCT00872950 | Unknown

• 1 other identifier: 2001-040
• Study Type: expanded_access
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine the effectiveness and adverse effects of 3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS).

Conditions

Lambert-Eaton Myasthenic Syndrome; Congenital Myasthenic Syndrome

Keywords

LEMS; CMS; 3,4 DIAMINOPYRIDINE; 3,4 DAP

Interventions

3,4-DIAMINOPYRIDINE DRUG

Treatment will begin with a low dose and will be increased as clinically needed as tolerated. The upper limit will be a total of 100mg/day.

Also known as: 3,4 DAP

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• LEMS diagnosis OR Pre or Post Synaptic CMS diagnosis
• years or older
• Females must have negative pregnancy test and be willing to practice an effective form of birth control
• No prolonged QT syndrome as indicated by baseline EKG

You may not qualify if:

• Known sensitivity to 3,4-DIAMINOPYRIDINE
• History of seizures and/or severe asthma

Sponsors & Collaborators

• Lahey Clinic: lead

Study Sites (1)

Lahey Hospital & Medical Center

Burlington, Massachusetts, 01805, United States

Location

Related Links

• Lahey Hospital \& Medical Center

MeSH Terms

Conditions

Lambert-Eaton Myasthenic Syndrome; Myasthenic Syndromes, Congenital

Interventions

Amifampridine

Condition Hierarchy (Ancestors)

Myasthenia Gravis; Paraneoplastic Syndromes, Nervous System; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Paraneoplastic Syndromes; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Neurodegenerative Diseases; Neuromuscular Junction Diseases; Neuromuscular Diseases; Autoimmune Diseases; Immune System Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

4-Aminopyridine; Aminopyridines; Amines; Organic Chemicals; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• Jayashri Srinivasan, MD,MCRP,PhD

  Lahey Clinic

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: expanded access
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 30, 2009
• First Posted: April 1, 2009
• Last Updated: April 11, 2022

Record last verified: 2022-03

Locations

US (1)